Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

about

Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.

P2860

Q39205101-0FB87A98-EAF9-428D-9949-7A28B0B3EDE7 Q39413114-8A200EA9-81CD-49C8-A635-6CCB466254AD

P2860

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

Item

http://www.wikidata.org/entity/Q38540859

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Outlook and Management of Pati ...... led by Hypomethylating Agents.

@en

type

Item

label

Outlook and Management of Pati ...... led by Hypomethylating Agents.

@en

prefLabel

Outlook and Management of Pati ...... led by Hypomethylating Agents.

@en

P1476

Outlook and Management of Pati ...... led by Hypomethylating Agents.

@en

P2093

Daniel A Roberts

http://www.w3.org/2001/XMLSchema#string

David P Steensma

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

Clinical effect of point mutations in myelodysplastic syndromes

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.

P2888

s11899-015-0273-2

P304

318-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-015-0273-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279519480

http://www.w3.org/2001/XMLSchema#string

P6179

1026990495

http://www.w3.org/2001/XMLSchema#string

P698

26126600

http://www.w3.org/2001/XMLSchema#string

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

about

P2860

P2860

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698